bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance

bioMérieux (Marcy-l’Étoile, France), a world leader in the field of in vitro diagnostics, has acquired LUMED (Sherbrooke, Canada), an innovative software company, by purchasing its entire share capital for close to EURO 9 million.

The proper usage of available data is vital for hospitals to deliver safe and appropriate patient care, and control pharmacy costs. The vast amounts of diagnostic and other vital data generated along the healthcare pathway analyzed by intelligent software can play a key role in assisting health professionals in their decision-making process, thus achieving optimal benefits for patients. LUMED has developed a clinical decision support system that aids hospitals in optimizing their antimicrobial prescriptions and monitoring healthcare-associated infections. LUMED’s advanced software solutions ensure that local antimicrobial prescription guidelines are adhered to and duly implemented. It provides all the varied and relevant information that healthcare professionals need to optimize their Antimicrobial Stewardship Programs (ASP) and their Infection Prevention and Control (IPC) programs, offer better care for their patients, fight antimicrobial resistance (AMR), and improve infection control.

Image: bioMérieux has acquired the entire share capital of LUMED for about EURO 9 million (Photo courtesy of LUMED)

LUMED’s solutions perfectly complement bioMérieux’s comprehensive suite of software solutions - BIOMÉRIEUX VISION SUITE - which gathers and organizes laboratory and hospital data into insightful and actionable information to support diagnostic and clinical decisions at all stages, from individual patient care to public health surveillance, to combat AMR and support antimicrobial stewardship. By providing a comprehensive suite of software products and services that collect, analyze, and merge various sources of data, BIOMÉRIEUX VISION SUITE empowers users to make the right decisions at the right time. The LUMED acquisition is in line with bioMérieux’s efforts to expand its data analytics portfolio, with continued focus and commitment to antimicrobial stewardship and infection prevention and control. bioMérieux plans to leverage its global commercial network to bring LUMED software’s benefits to the largest possible number of patients.

“For bioMérieux, it is essential that we extend the scope of diagnostic testing beyond the laboratory itself,” said Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux. “Today, many hospitals around the world are structuring themselves around the major issue of antimicrobial resistance and infection prevention. With LUMED, we provide solutions for antimicrobial stewardship teams to improve their daily workflow. The software contributes to optimizing the process of care delivery, as well as costs and patient management.”

"This acquisition marks a significant milestone in our journey,” added Vincent Nault, Chief Executive Officer, LUMED. “Joining forces with bioMérieux aligns with our commitment to advancing antimicrobial stewardship and infection prevention through our cutting-edge modules—such as APSS and ZINC. We believe that combining LUMED's innovative software solutions with bioMérieux's global reach and expertise in diagnostics will create a powerful synergy. Together, we can further enhance patient care, combat antimicrobial resistance, and contribute to the evolution of healthcare practices."

Related Links:
bioMérieux
LUMED